WEKO3
アイテム
Prophylaxis and treatment with mycophenolate mofetil in children with graft-versus-host disease undergoing allogeneic hematopoietic stem cell transplantation: a nationwide survey in Japan
http://hdl.handle.net/2237/00030561
http://hdl.handle.net/2237/000305615e0fc1dd-86f9-4ea8-b250-faffc9ef9f4f
名前 / ファイル | ライセンス | アクション |
---|---|---|
![]() |
|
|
![]() |
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2019-07-19 | |||||
タイトル | ||||||
タイトル | Prophylaxis and treatment with mycophenolate mofetil in children with graft-versus-host disease undergoing allogeneic hematopoietic stem cell transplantation: a nationwide survey in Japan | |||||
言語 | en | |||||
著者 |
Kawashima, Nozomu
× Kawashima, Nozomu× Iida, Minako× Suzuki, Ritsuro× Fukuda, Takahiro× Atsuta, Yoshiko× Hashii, Yoshiko× Inoue, Masami× Kobayashi, Masao× Yabe, Hiromasa× Okada, Keiko× Adachi, Souichi× Yuza, Yuki× Kawa, Keisei× Kato, Koji |
|||||
アクセス権 | ||||||
アクセス権 | open access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||
権利 | ||||||
言語 | en | |||||
権利情報 | “This is a post-peer-review, pre-copyedit version of an article published in [International Journal of Hematology]. The final authenticated version is available online at: http://dx.doi.org/10.1007/s12185-019-02601-5”. | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Mycophenolate mofetil | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Graft-versus-host disease | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Prophylaxis | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Treatment | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Pediatric | |||||
抄録 | ||||||
内容記述 | We investigated the safety and efficacy of mycophenolate mofetil (MMF) in the prevention and treatment of graft-versus-host disease (GVHD) using a nationwide retrospective survey in Japanese children undergoing hematopoietic stem cell transplantation (HSCT). Overall, 141 children undergoing allogeneic HSCT for hematological malignancy (n = 84), non-malignancy (n = 52), and solid tumors (n = 5) were administered MMF orally (median 8 years; range 0–15 years; 89 males and 52 females) during 1995–2011. Donors were primarily unrelated and mismatched related. In the GVHD prophylaxis group, 29% and 8.6% of patients developed grade II–IV and III–IV GVHD, respectively. Of the 32 evaluable patients, 16% developed chronic [limited (n = 4) and extensive (n = 1)] GVHD. In the acute GVHD treatment group, 61% had decreased grade. In the chronic GVHD treatment group, 36% had improved symptoms. Combined immunosuppressant was reduced or discontinued in 61% patients. Major adverse events (AEs) were neutropenia (4.3%), infection (3.5%), thrombocytopenia (2.1%), myelosuppression (2.1%), and diarrhea (1.4%). MMF dosage was reduced in two children due to grade ≥ 3 AEs; two children died from infection. MMF thus may be well tolerated in children, and may be an effective option for prophylaxis and treatment of acute and chronic GVHD. | |||||
言語 | en | |||||
内容記述タイプ | Abstract | |||||
内容記述 | ||||||
内容記述 | ファイル公開:2020/04/01 | |||||
言語 | ja | |||||
内容記述タイプ | Other | |||||
出版者 | ||||||
言語 | en | |||||
出版者 | Elsevier | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプresource | http://purl.org/coar/resource_type/c_6501 | |||||
タイプ | journal article | |||||
出版タイプ | ||||||
出版タイプ | AM | |||||
出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
DOI | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | DOI | |||||
関連識別子 | https://doi.org/10.1007/s12185-019-02601-5 | |||||
ISSN(print) | ||||||
収録物識別子タイプ | PISSN | |||||
収録物識別子 | 0925-5710 | |||||
書誌情報 |
en : International Journal of Hematology 巻 109, 号 4, p. 491-498, 発行日 2019-04 |
|||||
著者版フラグ | ||||||
値 | author |